Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: A systematic review and meta-analysis

Yunfeng Zhang, Zhibin Wu, Dapeng Liu, Meng Wang, Guodong Xiao, Peili Wang, Xin Sun, Hong Ren, Shou-Ching Tang, Ning Du

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Polo-like kinases 1 (PLK1), a key regulator of mitosis, plays an essential role in maintaining genomic stability. Up-regulation of PLK1 was found in tumorigenesis and tumor progression of diverse cancers. However, the clinicopathological and prognostic implications of PLK1 in breast cancer (BC) have yet to be unveiled. Therefore, using PubMed, Web of Science, Embase, and Chinese databases, we conducted a metaanalysis to define the potential clinical value of PLK1 in BC. Eleven eligible articles with 2481 patients enrolled were included in the present meta-analysis, of which eight studies reported on the relationship between PLK1 expression and clinicopathological features, and nine studies provided survival data in BC patients. Furthermore, the results revealed that high PLK1 levels were significantly associated with larger tumor size (OR=1.703, 95%CIs: 1.315-2.205, P < 0.001), higher pathological grading (OR=6.028, 95%CIs: 2.639-13.772, P < 0.001), and lymph node metastasis (OR= 1.524, 95%CIs: 1.192-1.950, P=0.001). Moreover, PLK1 was found to be a valuable factor for distinguishing lobular BC from ductal BC with the pooled OR=0.215(95%CIs: 0.083-0.557, P=0.002). Analysis of included data showed that high PLK1 expression significantly indicated worse overall survival for BC patients (HR= 3.438, 95%CIs: 2.293-5.154, P < 0.001), as well as worse cancer specific survival and disease-free survival (HR=2.414, 95%CIs: 1.633-3.567, P < 0.001 and HR= 2.261, 95%CIs: 1.796- 2.951, P < 0.001, respectively). This quantitative meta-analysis suggests that high PLK1 expression is a credible indicator for the progression of BC and confirms a higher risk of a worse survival rate in patients with BC.

Original languageEnglish (US)
Pages (from-to)57723-57732
Number of pages10
JournalOncotarget
Volume8
Issue number34
DOIs
StatePublished - Jan 1 2017

Fingerprint

Meta-Analysis
Breast
Breast Neoplasms
Survival
Neoplasms
polo-like kinase 1
Genomic Instability
Mitosis
PubMed
Disease-Free Survival
Carcinogenesis
Up-Regulation
Survival Rate
Lymph Nodes
Databases
Neoplasm Metastasis

Keywords

  • Breast cancer
  • Clinical outcome
  • Meta-analysis
  • Polo-like kinas 1

ASJC Scopus subject areas

  • Oncology

Cite this

Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients : A systematic review and meta-analysis. / Zhang, Yunfeng; Wu, Zhibin; Liu, Dapeng; Wang, Meng; Xiao, Guodong; Wang, Peili; Sun, Xin; Ren, Hong; Tang, Shou-Ching; Du, Ning.

In: Oncotarget, Vol. 8, No. 34, 01.01.2017, p. 57723-57732.

Research output: Contribution to journalReview article

Zhang, Y, Wu, Z, Liu, D, Wang, M, Xiao, G, Wang, P, Sun, X, Ren, H, Tang, S-C & Du, N 2017, 'Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: A systematic review and meta-analysis', Oncotarget, vol. 8, no. 34, pp. 57723-57732. https://doi.org/10.18632/oncotarget.17301
Zhang, Yunfeng ; Wu, Zhibin ; Liu, Dapeng ; Wang, Meng ; Xiao, Guodong ; Wang, Peili ; Sun, Xin ; Ren, Hong ; Tang, Shou-Ching ; Du, Ning. / Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients : A systematic review and meta-analysis. In: Oncotarget. 2017 ; Vol. 8, No. 34. pp. 57723-57732.
@article{504a5cd992a0494495c8a52da73ff8d0,
title = "Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: A systematic review and meta-analysis",
abstract = "Polo-like kinases 1 (PLK1), a key regulator of mitosis, plays an essential role in maintaining genomic stability. Up-regulation of PLK1 was found in tumorigenesis and tumor progression of diverse cancers. However, the clinicopathological and prognostic implications of PLK1 in breast cancer (BC) have yet to be unveiled. Therefore, using PubMed, Web of Science, Embase, and Chinese databases, we conducted a metaanalysis to define the potential clinical value of PLK1 in BC. Eleven eligible articles with 2481 patients enrolled were included in the present meta-analysis, of which eight studies reported on the relationship between PLK1 expression and clinicopathological features, and nine studies provided survival data in BC patients. Furthermore, the results revealed that high PLK1 levels were significantly associated with larger tumor size (OR=1.703, 95{\%}CIs: 1.315-2.205, P < 0.001), higher pathological grading (OR=6.028, 95{\%}CIs: 2.639-13.772, P < 0.001), and lymph node metastasis (OR= 1.524, 95{\%}CIs: 1.192-1.950, P=0.001). Moreover, PLK1 was found to be a valuable factor for distinguishing lobular BC from ductal BC with the pooled OR=0.215(95{\%}CIs: 0.083-0.557, P=0.002). Analysis of included data showed that high PLK1 expression significantly indicated worse overall survival for BC patients (HR= 3.438, 95{\%}CIs: 2.293-5.154, P < 0.001), as well as worse cancer specific survival and disease-free survival (HR=2.414, 95{\%}CIs: 1.633-3.567, P < 0.001 and HR= 2.261, 95{\%}CIs: 1.796- 2.951, P < 0.001, respectively). This quantitative meta-analysis suggests that high PLK1 expression is a credible indicator for the progression of BC and confirms a higher risk of a worse survival rate in patients with BC.",
keywords = "Breast cancer, Clinical outcome, Meta-analysis, Polo-like kinas 1",
author = "Yunfeng Zhang and Zhibin Wu and Dapeng Liu and Meng Wang and Guodong Xiao and Peili Wang and Xin Sun and Hong Ren and Shou-Ching Tang and Ning Du",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.17301",
language = "English (US)",
volume = "8",
pages = "57723--57732",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "34",

}

TY - JOUR

T1 - Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients

T2 - A systematic review and meta-analysis

AU - Zhang, Yunfeng

AU - Wu, Zhibin

AU - Liu, Dapeng

AU - Wang, Meng

AU - Xiao, Guodong

AU - Wang, Peili

AU - Sun, Xin

AU - Ren, Hong

AU - Tang, Shou-Ching

AU - Du, Ning

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Polo-like kinases 1 (PLK1), a key regulator of mitosis, plays an essential role in maintaining genomic stability. Up-regulation of PLK1 was found in tumorigenesis and tumor progression of diverse cancers. However, the clinicopathological and prognostic implications of PLK1 in breast cancer (BC) have yet to be unveiled. Therefore, using PubMed, Web of Science, Embase, and Chinese databases, we conducted a metaanalysis to define the potential clinical value of PLK1 in BC. Eleven eligible articles with 2481 patients enrolled were included in the present meta-analysis, of which eight studies reported on the relationship between PLK1 expression and clinicopathological features, and nine studies provided survival data in BC patients. Furthermore, the results revealed that high PLK1 levels were significantly associated with larger tumor size (OR=1.703, 95%CIs: 1.315-2.205, P < 0.001), higher pathological grading (OR=6.028, 95%CIs: 2.639-13.772, P < 0.001), and lymph node metastasis (OR= 1.524, 95%CIs: 1.192-1.950, P=0.001). Moreover, PLK1 was found to be a valuable factor for distinguishing lobular BC from ductal BC with the pooled OR=0.215(95%CIs: 0.083-0.557, P=0.002). Analysis of included data showed that high PLK1 expression significantly indicated worse overall survival for BC patients (HR= 3.438, 95%CIs: 2.293-5.154, P < 0.001), as well as worse cancer specific survival and disease-free survival (HR=2.414, 95%CIs: 1.633-3.567, P < 0.001 and HR= 2.261, 95%CIs: 1.796- 2.951, P < 0.001, respectively). This quantitative meta-analysis suggests that high PLK1 expression is a credible indicator for the progression of BC and confirms a higher risk of a worse survival rate in patients with BC.

AB - Polo-like kinases 1 (PLK1), a key regulator of mitosis, plays an essential role in maintaining genomic stability. Up-regulation of PLK1 was found in tumorigenesis and tumor progression of diverse cancers. However, the clinicopathological and prognostic implications of PLK1 in breast cancer (BC) have yet to be unveiled. Therefore, using PubMed, Web of Science, Embase, and Chinese databases, we conducted a metaanalysis to define the potential clinical value of PLK1 in BC. Eleven eligible articles with 2481 patients enrolled were included in the present meta-analysis, of which eight studies reported on the relationship between PLK1 expression and clinicopathological features, and nine studies provided survival data in BC patients. Furthermore, the results revealed that high PLK1 levels were significantly associated with larger tumor size (OR=1.703, 95%CIs: 1.315-2.205, P < 0.001), higher pathological grading (OR=6.028, 95%CIs: 2.639-13.772, P < 0.001), and lymph node metastasis (OR= 1.524, 95%CIs: 1.192-1.950, P=0.001). Moreover, PLK1 was found to be a valuable factor for distinguishing lobular BC from ductal BC with the pooled OR=0.215(95%CIs: 0.083-0.557, P=0.002). Analysis of included data showed that high PLK1 expression significantly indicated worse overall survival for BC patients (HR= 3.438, 95%CIs: 2.293-5.154, P < 0.001), as well as worse cancer specific survival and disease-free survival (HR=2.414, 95%CIs: 1.633-3.567, P < 0.001 and HR= 2.261, 95%CIs: 1.796- 2.951, P < 0.001, respectively). This quantitative meta-analysis suggests that high PLK1 expression is a credible indicator for the progression of BC and confirms a higher risk of a worse survival rate in patients with BC.

KW - Breast cancer

KW - Clinical outcome

KW - Meta-analysis

KW - Polo-like kinas 1

UR - http://www.scopus.com/inward/record.url?scp=85029053394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029053394&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.17301

DO - 10.18632/oncotarget.17301

M3 - Review article

AN - SCOPUS:85029053394

VL - 8

SP - 57723

EP - 57732

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -